Transgene Biotek
BSE: TRABI · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Transgene Biotek's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Transgene Biotek is a Hyderabad-based biotechnology firm focused on the research and development of biopharmaceuticals, including oncology, autoimmunity, and metabolic disease treatments. The company leverages advanced technologies like RNA interference and monoclonal antibodies to develop novel drug delivery systems and biosimilars.
Business Model
The company operates as a research-driven biotech entity aiming to commercialise its pipeline of drug candidates, vaccines, and generic oncology products. It seeks to generate revenue through the eventual licensing or market launch of its therapeutic solutions.
Management Commentary
Management is focused on transitioning the company's extensive research pipeline into commercialised therapeutic solutions for both domestic and global markets.
Growth Outlook
Growth is expected to be driven by the advancement of its drug candidate portfolio, specifically focusing on oral insulin, vaccines, and biosimilars. The company aims to address unmet medical needs to secure a stronger position in the competitive biotech landscape.
Key Risks
- Regulatory Hurdles. The company faces significant risks related to the lengthy and stringent clinical trial and drug approval processes required by health authorities.
- Financial Sustainability. Historical financial challenges may impact the company's ability to fund long-term research and development projects to completion.
- R&D Failure. As a biotech firm, there is an inherent risk that drug candidates may fail to demonstrate the required efficacy or safety during clinical development.
- Market Competition. The company operates in a highly competitive sector where larger, better-capitalised firms may bring similar biosimilars or therapies to market more rapidly.
Start your research today
Unlock AI insights, financials, peers and live data on Transgene Biotek and 5,000+ companies — free.
Peers · Healthcare Service Provider
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Transgene BiotekTRABI | ₹19 Cr | — | — | — | -257.1% | — | — | -25.3% |
Krsnaa Diagnostics Ltd.KRSNAA | ₹1,830 Cr | 18.76 | 8.80 | 10.2% | 32.5% | 10.5% | 13.3% | -28.5% |
Suraksha Diagnostic Ltd.SURAKSHA | ₹1,772 Cr | 48.60 | 16.73 | 22.5% | 32.7% | 15.8% | 18.6% | +14.0% |
3B BlackBio Dx Ltd3BBLACKBIO | ₹1,237 Cr | 20.61 | 14.59 | 41.9% | 58.0% | 21.2% | 26.3% | +0.5% |
One Global Service Provider LimitedONEGLOBAL | ₹1,068 Cr | — | — | — | 19.0% | — | — | +114.9% |
Gaudium IVF and Women Health LimitedGAUDIUMIVF | ₹886 Cr | — | — | — | 36.0% | — | — | — |
As of Mar 2026
Financials
Transgene Biotek
BSE: TRABI · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Transgene Biotek's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Transgene Biotek is a Hyderabad-based biotechnology firm focused on the research and development of biopharmaceuticals, including oncology, autoimmunity, and metabolic disease treatments. The company leverages advanced technologies like RNA interference and monoclonal antibodies to develop novel drug delivery systems and biosimilars.
Business Model
The company operates as a research-driven biotech entity aiming to commercialise its pipeline of drug candidates, vaccines, and generic oncology products. It seeks to generate revenue through the eventual licensing or market launch of its therapeutic solutions.
Management Commentary
Management is focused on transitioning the company's extensive research pipeline into commercialised therapeutic solutions for both domestic and global markets.
Growth Outlook
Growth is expected to be driven by the advancement of its drug candidate portfolio, specifically focusing on oral insulin, vaccines, and biosimilars. The company aims to address unmet medical needs to secure a stronger position in the competitive biotech landscape.
Key Risks
- Regulatory Hurdles. The company faces significant risks related to the lengthy and stringent clinical trial and drug approval processes required by health authorities.
- Financial Sustainability. Historical financial challenges may impact the company's ability to fund long-term research and development projects to completion.
- R&D Failure. As a biotech firm, there is an inherent risk that drug candidates may fail to demonstrate the required efficacy or safety during clinical development.
- Market Competition. The company operates in a highly competitive sector where larger, better-capitalised firms may bring similar biosimilars or therapies to market more rapidly.
Start your research today
Unlock AI insights, financials, peers and live data on Transgene Biotek and 5,000+ companies — free.
Peers · Healthcare Service Provider
As of Mar 2026